Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBarr (A.G.) Regulatory News (BAG)

Share Price Information for Barr (A.G.) (BAG)

Share Price is delayed by 15 minutes
Get Live Data
608.00    -5.00 (-0.82%)
Bid:
608.00
Ask:
610.00
Spread: 2.00 (0.329%)
Market Cap: £674.73m
BAG Live PriceLast checked at - London Stock Exchange

Intraday Barr (A.G.) Share Chart

Trading Statement

29 Jul 2025 07:00

RNS Number : 8564S
Barr(A.G.) PLC
29 July 2025
 

IMMEDIATE RELEASE 29 July 2025

A.G. BARR p.l.c

("A.G. BARR" or "the Company")

 

Trading Update

 

Continued revenue & profit growth; Full Year expectations unchanged

 

A.G. BARR p.l.c., the multi-beverage business with a portfolio of market-leading UK brands including IRN-BRU, Rubicon, Boost and FUNKIN, today announces a trading update for the 26 weeks ended 26 July 2025 (H1 2025/26).

H1 2025/26 Trading

H1 2025/26 revenue is expected to be c.£228m, c.3% up on the prior year (H1 2024/25: £221.3m). Overall, the Company's trading momentum increased as H1 progressed, with several record volume weeks in Q2.

Brand revenue performance was led by Boost which delivered strong double-digit growth. IRN-BRU and Rubicon were flat in H1, with a stronger performance in Q2. FUNKIN saw continued off-trade growth partly mitigating challenges in on-trade, with the overall trend improving during H1 and positive in Q2. 

H1 adjusted operating margin is anticipated to be ahead of last year at c.15.0% (H1 2024/25: 13.0%) driven by improved manufacturing efficiencies, on-going benefits from our strategic business improvement initiatives and continued disciplined cost management.

Strategy Update

We are pleased to announce the Company has acquired a 50.1% equity stake in Innate-Essence Ltd, for an initial consideration of £15 million. Innate-Essence is the home of The Turmeric Co., a leading brand in the functional shots market, as well as a number of other speciality health drinks.

This is consistent with the Company's strategy of acquisitions and innovation in high growth, health focused, functional beverage categories. The investment has been funded from the Company's net cash position. It is not expected to have a significant impact on revenue or profit in the current financial year.

The Company has also concluded the sale of the Strathmore brand and the Forfar production site to Tŷ Nant, negatively impacting revenue in the short-term but not profit.

Full Year Outlook

Our revenue and profit growth expectations for the full year are unchanged. We are confident that H2 will see a strong rate of year-on-year revenue growth. We have made excellent progress with operating margin during H1 and expect to deliver a full year result in line with expectations after taking into account a planned higher level of marketing activity in H2.

Euan Sutherland, Chief Executive Officer, commented:

"We are pleased to report continued revenue growth and strong profit growth in the first half of the financial year. Trading improved during H1 and we enter H2 with strong momentum and continued progress on margin improvement as our strategic initiatives continue to deliver. I am also excited about our expansion into the functional beverage segment working alongside Thomas Robson-Kanu and the Innate-Essence team. Our full year guidance remains unchanged and in line with market expectations."

For more information, please contact :

A.G. BARR  MHP GROUP

0330 390 3900 07801 894 577

Euan Sutherland, Chief Executive Officer agbarr@mhpgroup.com

Stuart Lorimer, Chief Finance and Operating Officer Oliver Hughes

Ewan Dytch, Corporate Finance Director Rachel Farrington

Veronica Farah

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUWOSRVSUBUAR
Date   Source Headline
2nd Aug 20177:00 amRNSTrading Update
28th Jul 20175:00 pmRNSClose period repurchase programme
26th Jul 20177:00 amRNSTransaction in Own Shares
25th Jul 20171:45 pmRNSDirector/PDMR Shareholding
25th Jul 20177:00 amRNSTransaction in Own Shares
24th Jul 20171:37 pmRNSDirector/PDMR Shareholding
17th Jul 20178:09 amRNSTransaction in Own Shares
14th Jul 20177:43 amRNSTransaction in Own Shares
13th Jul 201710:07 amRNSNotice of Trading Update
10th Jul 20172:21 pmRNSDirector/PDMR Shareholding
28th Jun 20177:13 amRNSTransaction in Own Shares
27th Jun 201712:14 pmRNSTransaction in Own Shares
14th Jun 20173:25 pmRNSDirector/PDMR Shareholding
14th Jun 20177:00 amRNSTransaction in Own Shares
13th Jun 20177:14 amRNSTransaction in Own Shares
12th Jun 20171:33 pmRNSDirector/PDMR Shareholding
12th Jun 20171:32 pmRNSDirector/PDMR Shareholding
12th Jun 20171:30 pmRNSDirector/PDMR Shareholding
12th Jun 20171:28 pmRNSDirector/PDMR Shareholding
8th Jun 20172:02 pmRNSDirector/PDMR Shareholding
6th Jun 20174:04 pmRNSDirector/PDMR Shareholding
31st May 201712:38 pmRNSAGM Statement
18th May 20177:00 amRNSTransaction in Own Shares
9th May 20171:20 pmRNSDirector/PDMR Shareholding
3rd May 20179:43 amRNSDirector/PDMR Shareholding
27th Apr 20174:08 pmRNSAnnual Report and Accounts and Notice of AGM
26th Apr 201712:17 pmRNSDirector/PDMR Shareholding
10th Apr 201712:12 pmRNSDirector/PDMR Shareholding
3rd Apr 20173:47 pmRNSDirector/PDMR Shareholding
28th Mar 20177:00 amRNSFinal Results
8th Mar 20172:49 pmRNSDirector/PDMR Shareholding
1st Mar 20177:00 amRNSFurther reduction of sugar across portfolio
8th Feb 20171:34 pmRNSDirector/PDMR Shareholding
1st Feb 20177:00 amRNSTrading Update
12th Jan 20177:00 amRNSNotice of Trading Update
10th Jan 20172:10 pmRNSDirector/PDMR Shareholding
9th Jan 20174:35 pmRNSPrice Monitoring Extension
9th Jan 20172:56 pmRNSDirector Declaration
13th Dec 20167:00 amRNSAnalyst Site Visit
8th Dec 201612:42 pmRNSDirector/PDMR Shareholding
14th Nov 201611:23 amRNSHolding(s) in Company
10th Nov 20162:59 pmRNSHolding(s) in Company
8th Nov 201612:42 pmRNSDirector/PDMR Shareholding
25th Oct 201611:33 amRNSDirector/PDMR Shareholding
25th Oct 201611:20 amRNSDirector/PDMR Shareholding
25th Oct 201611:19 amRNSDirector/PDMR Shareholding
25th Oct 201611:13 amRNSDirector/PDMR Shareholding
10th Oct 20161:27 pmRNSDirector/PDMR Shareholding
28th Sep 20162:13 pmRNSCorrection: Interim Results
27th Sep 20167:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.